Eloxx Pharmaceuticals, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
480 Arsenal Way, Suite 130, Watertown, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Sevion Therapeutics, Inc. (to 12/22/2017), SENESCO TECHNOLOGIES INC (to 9/29/2014), NAVA LEISURE USA INC (to 5/24/1999)
Latest financial report
10-Q - Q3 2023 - Nov 13, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 43 % -78.8%
Debt-to-equity -321 % -184%
Return On Equity 248 %
Return On Assets -203 % -80.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.14M shares -96.4%
Common Stock, Shares, Outstanding 2.17M shares -97.5%
Common Stock, Value, Issued 31K USD -96.4%
Weighted Average Number of Shares Outstanding, Basic 2.75M shares +26.8%
Weighted Average Number of Shares Outstanding, Diluted 2.75M shares +26.8%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 8.92M USD -23.7%
Operating Income (Loss) -19.3M USD +51.8%
Net Income (Loss) Attributable to Parent -20.5M USD +51%
Earnings Per Share, Basic -9.07 USD/shares +62.2%
Earnings Per Share, Diluted -9.07 USD/shares +62.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.78M USD -80.6%
Assets, Current 5.63M USD -78.1%
Property, Plant and Equipment, Net 107K USD -50.2%
Operating Lease, Right-of-Use Asset 306K USD -69.2%
Assets 6.04M USD -77.5%
Accounts Payable, Current 3.13M USD +96.5%
Employee-related Liabilities, Current 122K USD -74.8%
Accrued Liabilities, Current 2.44M USD -46%
Liabilities, Current 23.5M USD +8.24%
Operating Lease, Liability, Noncurrent 3K USD -99.1%
Liabilities 26.1M USD -18.1%
Retained Earnings (Accumulated Deficit) -289M USD -7.64%
Stockholders' Equity Attributable to Parent -20M USD -302%
Liabilities and Equity 6.04M USD -77.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.81M USD +28.2%
Net Cash Provided by (Used in) Financing Activities -7.5M USD -207%
Net Cash Provided by (Used in) Investing Activities 11K USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 3.07M shares -96.5%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.3M USD -472%
Interest Paid, Excluding Capitalized Interest, Operating Activities 430K USD +44.8%
Depreciation 71K USD -40.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Property, Plant and Equipment, Gross 331K USD -16.8%
Operating Lease, Liability, Current 315K USD -54.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.4M USD -25.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%